Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9318
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLee, Fook-Theanen
dc.contributor.authorRigopoulos, Angelaen
dc.contributor.authorHall, Cen
dc.contributor.authorClarke, Ken
dc.contributor.authorCody, S Hen
dc.contributor.authorSmyth, Fiona Een
dc.contributor.authorLiu, Zen
dc.contributor.authorBrechbiel, Martin Wen
dc.contributor.authorHanai, Nen
dc.contributor.authorNice, Edouard Cen
dc.contributor.authorCatimel, Ben
dc.contributor.authorBurgess, Antony Wen
dc.contributor.authorWelt, Sen
dc.contributor.authorRitter, Gen
dc.contributor.authorOld, Lloyd Jen
dc.contributor.authorScott, Andrew Men
dc.date.accessioned2015-05-15T22:22:19Z
dc.date.available2015-05-15T22:22:19Z
dc.date.issued2001-06-01en
dc.identifier.citationCancer Research; 61(11): 4474-82en
dc.identifier.govdoc11389078en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/9318en
dc.description.abstractThe chimeric monoclonal antibody KM871, directed against the G(D3) antigen, is under evaluation for its potential to target melanoma. To facilitate the in vivo evaluation of biodistribution properties and measurement of pharmacokinetics, KM871 was radiolabeled with (125)I via tyrosine residues and with (111)In via the bifunctional metal ion chelator C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid (CHX-A"-DTPA) to lysine residues. Using antigen-positive SK-MEL-28 melanoma cells, immunoreactivities of 42 and 40% cell binding were obtained, respectively, for the two radioconjugates. Binding was enhanced in the presence of added unlabeled antibody. A humanized A33 antibody was similarly labeled with the two isotopes and used as a control. To determine and compare in vivo biodistribution characteristics of KM871 radiolabeled with (111)In or (125)I, mixtures of the radioconjugates were injected i.v. into BALB/c nude mice bearing G(D3)-positive-SK-MEL-28 melanoma xenografts. Gamma camera images were acquired; groups of five mice were sacrificed at various time intervals, and tumors, blood, and tissues were analyzed. (111)In-labeled CHX-A"-DTPA-KM871 showed a maximum tumor uptake of 41.9 +/- 7.0% injected dose/g at 72 h with prolonged retention over a 15-day period. The tumor:blood ratio was 3:1 by 72 h, and higher ratios were observed at later time points. No abnormal accumulation of (111)In-labeled conjugate was found in normal tissues. In contrast, there was little accumulation of (125)I-labeled KM871 in the same tumors. The specificity of antibody localization was confirmed by the low tumor uptake values for radiolabeled control antibody. Gamma camera imaging demonstrated excellent uptake of (111)In-labeled CHX-A"-DTPA-KM871 in the xenografts. Chromatographic analyses of xenograft cytosolic extracts demonstrated tumor internalization and catabolism of radiolabeled KM871 with the formation of small molecular weight metabolites. Laser scanning confocal microscopy demonstrated that the majority of intracellular KM871 is localized to lysosomes. Despite the catabolism of the radioconjugate, a dose-dependent increase in KM871 tumor localization was shown through immunohistochemical examination of xenograft biopsies. This study demonstrates for the first time the in vivo localization of a radiolabeled anti-G(D3) monoclonal antibody to G(D3)-expressing xenografts using gamma camera scanning techniques and tumor cell internalization of KM871 tagged with a green fluorescent dye, Alexa Fluor 488, through confocal microscopy. KM871 has potential for targeting tumors in patients with melanoma.en
dc.language.isoenen
dc.subject.otherAnimalsen
dc.subject.otherAntibodies, Monoclonal.diagnostic use.immunology.pharmacokineticsen
dc.subject.otherChelating Agents.chemistry.pharmacokineticsen
dc.subject.otherFemaleen
dc.subject.otherGamma Camerasen
dc.subject.otherGangliosides.biosynthesis.immunologyen
dc.subject.otherHumansen
dc.subject.otherImmunoconjugates.diagnostic use.pharmacokineticsen
dc.subject.otherImmunohistochemistryen
dc.subject.otherIndium Radioisotopes.chemistry.diagnostic useen
dc.subject.otherIodine Radioisotopes.chemistry.diagnostic useen
dc.subject.otherIsothiocyanates.chemistry.pharmacokineticsen
dc.subject.otherIsotope Labelingen
dc.subject.otherMelanoma.immunology.metabolism.radionuclide imagingen
dc.subject.otherMiceen
dc.subject.otherMice, Inbred BALB Cen
dc.subject.otherMice, Nudeen
dc.subject.otherPentetic Acid.analogs & derivatives.chemistry.pharmacokineticsen
dc.subject.otherRadiopharmaceuticals.diagnostic use.pharmacokineticsen
dc.subject.otherRecombinant Fusion Proteins.immunology.pharmacokineticsen
dc.subject.otherTissue Distributionen
dc.subject.otherTumor Cells, Cultureden
dc.subject.otherXenograft Model Antitumor Assaysen
dc.titleSpecific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.en
dc.typeJournal Articleen
dc.identifier.journaltitleCancer researchen
dc.identifier.affiliationLudwig Institute For Cancer Research, Melbourne Branch, Austin and Repatriation Medical Centre, Studley Road, Heidelberg, Victoria 3084, Australiaen
dc.description.pages4474-82en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/11389078en
dc.type.austinJournal Articleen
local.name.researcherScott, Andrew M
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.languageiso639-1en-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

48
checked on Dec 31, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.